Work

Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-7942

Authors: Tara Graff, Savreet Bains Chawla, Monika Jun, Nicole Heaps, Abualbishr Alshreef, David Tybor, Nadine Zawadzki, Kathryn Spurrier, Jason Shafrin

Institutions: Genmab (United States), AbbVie (United States), Los Angeles Police Department

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417016674

Cites:

Cited by:

Related to: